CIK 0001599298 · Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 371979717
- Phone
- 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-21 | Xia Yu Director | Purchase | +533,617 | $18.74 | $10.0M | 32,057,147 |
| 2025-10-21 | Anand Bhaskar Chief Accounting Officer | Grant or award | +26,680 | $18.74 | $500K | 159,751 |
| 2025-10-21 | Soni Manmeet Singh COO and CFO | Grant or award | +53,361 | $18.74 | $1000K | 3,073,603 |
| 2025-10-21 | Zanganeh Mahkam Co-Chief Executive Officer | Grant or award | +266,808 | $18.74 | $5.0M | 25,724,474 |
| 2025-10-21 | Zanganeh Mahkam Co-Chief Executive Officer | Purchase | +26,680 | $18.74 | $500K | 76,680 |
| 2025-10-21 | Zanganeh Mahkam Co-Chief Executive Officer | Grant or award | +13,980,789 | $18.74 | $262.0M | 570,073,879 |
| 2025-10-21 | DUGGAN ROBERT W Co-Chief Executive Officer | Grant or award | +13,980,789 | $18.74 | $262.0M | 570,073,879 |
| 2025-10-21 | DUGGAN ROBERT W Co-Chief Executive Officer | Grant or award | +266,808 | $18.74 | $5.0M | 25,724,474 |
| 2025-10-21 | DUGGAN ROBERT W Co-Chief Executive Officer | Purchase | +26,680 | $18.74 | $500K | 76,680 |
| 2025-09-18 | Anand Bhaskar Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-09-11 | Zanganeh Mahkam Co-Chief Executive Officer | Purchase | +5,000 | $18.07 | $90K | 556,093,090 |
| 2025-09-11 | DUGGAN ROBERT W Co-Chief Executive Officer | Purchase | +5,000 | $18.07 | $90K | 556,093,090 |
| 2025-09-10 | Zanganeh Mahkam Co-Chief Executive Officer | Purchase | +333,394 | $17.68 | $5.9M | 556,088,090 |
| 2025-09-10 | DUGGAN ROBERT W Co-Chief Executive Officer | Purchase | +333,394 | $17.68 | $5.9M | 556,088,090 |
| 2025-05-30 | Zanganeh Mahkam Co-Chief Executive Officer | Option exercise | +74,545 | $2.64 | $197K | 555,754,696 |
| 2025-05-30 | Zanganeh Mahkam Co-Chief Executive Officer | Option exercise · Stock Option (right to buy) | −74,545 | 0 | ||
| 2025-05-30 | DUGGAN ROBERT W Co-Chief Executive Officer | Option exercise | +74,545 | $2.64 | $197K | 555,754,696 |
| 2025-05-30 | DUGGAN ROBERT W Co-Chief Executive Officer | Option exercise · Stock Option (right to buy) | −74,545 | 0 | ||
| 2025-04-29 | Anand Bhaskar Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +600,000 | 600,000 | ||
| 2025-04-29 | Anand Bhaskar Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 |
Page 2 of 9 · 163 trades